ANTICOAGULANT MARKET ANALYSIS

Anticoagulant Market, By Drug Class (Novel Oral Anticoagulants (NOACs), Heparin and Low-molecular- weight Heparin(LMWH), and Vitamin K Antagonist), By Application (Atrial Fibrillation/Myocardial Infarction (Heart Attack), Deep Vein Thrombosis (DVT), Pulmonary Embolism, and Other Applications), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Jan 2023
Code : CMI5486
Pages :169
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Anticoagulant Market: Key Developments

In October 2019, Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved Xarelto (Rivaroxaban) for the prevention of venous thromboembolism (VTE).

In March 2019, Bristol-Myers Squibb-Pfizer Alliance announced results of Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs) in individuals with non-valvular atrial fibrillation (NVAF) and recent acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI).